Compare Abeona Therapeutics Inc (ABEO) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bill.com Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Bill.com Holdings Inc trades at $39.36 (market cap $4.05B). The key difference: Bill.com Holdings Inc is far larger — about 10.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BILL | |
|---|---|---|
Market Cap | $373.32M | $4.05B |
Sector | Health | Technology |
52-Week High | $7.23 | $56.32 |
52-Week Low | $4.17 | $31.96 |
Enterprise Value | $228.22M | $3.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BILL Holdings trades at $40.68, up 0.49% today, with strong analyst consensus pointing to a $48 price target. The stock shows bullish technical momentum with recent earnings beats and revenue growth from $1.3B to $1.46B in 2025. Recent executive appointments and AI focus signal strategic positioning for growth.
Outlook remains positive with 56% analyst buy ratings and 36% upside potential, though high P/E of 214 and thin net margins of 0.01% pose valuation risks. Key catalysts include continued earnings outperformance and AI integration, while macroeconomic sensitivity and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
